Amputation of Lower Limb DRG 618 - Medicare Reimbursement

DRG 618 addresses inpatient lower limb amputation cases related to endocrine, nutritional, and metabolic disorders without Major Complication or Comorbidity and without Complication or Comorbidity. Understanding this Diagnosis-Related Group is important because it determines the Medicare prospective payment for the hospital stay based on clinical grouping and expected resource use.

DRG 618 Overview

DRG 618 covers inpatient episodes involving amputation of the lower limb when the principal clinical indication is an endocrine, nutritional, or metabolic disorder and there are no Major Complication or Comorbidity and no Complication or Comorbidity present. This Diagnosis-Related Group groups cases by clinical similarity and resource use to determine Medicare payment for the inpatient stay. It matters for Medicare payment because the assigned Diagnosis-Related Group affects the prospective payment amount hospitals receive. Proper classification influences reimbursement for surgical, perioperative, and postoperative hospital resources.

Acute perioperative optimization trials focusing on limb-salvage versus primary amputation strategies in patients with diabetic or other metabolic-related peripheral arterial disease: these studies enroll hospitalized patients facing potential lower-limb amputation to compare immediate surgical decision pathways (revascularization attempts, limited/partial amputation, or primary transtibial/femoral amputation) and measure short-term outcomes such as reoperation, wound complications, ICU/hospital length of stay, and 30-day mortality. The patient population is typically older adults with diabetes, chronic kidney disease, or peripheral neuropathy with ischemic or infective limb-threatening pathology; results inform surgeons and hospitalists on which acute interventions reduce perioperative morbidity and resource utilization. This research is relevant to providers and payers because it targets high-cost inpatient decisions that directly affect LOS, readmission risk, and intensive resource use in DRG 618 admissions.
Comparative effectiveness studies of perioperative infection control and wound-healing strategies in metabolic-disease-related amputations: randomized or pragmatic trials evaluate different perioperative protocols (antibiotic stewardship strategies, negative-pressure wound therapy, optimized glycemic control bundles, and standardized debridement timing) in patients with diabetes-related foot infections who undergo major lower-limb amputation. These trials study inpatient and early post-discharge outcomes such as surgical site infection rates, stump healing time, need for revision/amputation level escalation, and short-term functional status, targeting a population with impaired healing physiology. Findings are directly applicable to clinical pathways and payer policies because improved protocols can reduce complications, shorten stays, and lower downstream costs associated with reoperations and extended rehabilitation.
Post-discharge rehabilitation, secondary prevention, and cost-outcome cohort studies assessing functional recovery and readmission in patients after lower-limb amputation for endocrine/metabolic disorders: prospective observational studies or randomized rehabilitation trials follow patients after discharge to compare prosthetic fitting timelines, multidisciplinary rehabilitation models, home health intensity, and secondary prevention (glycemic, vascular risk) interventions on 90- to 365-day outcomes including mobility, quality of life, prosthesis use, readmissions, and total episode-of-care costs. The enrolled population includes survivors of inpatient amputation with diabetes or metabolic comorbidities who are at high risk for recurrent limb events and hospital utilization; this research helps identify which post-acute care strategies yield the best functional and economic outcomes. Results matter to providers and payers by guiding resource allocation for durable medical equipment, rehab services, and transitional care programs that can reduce long-term costs and improve patient independence.

Acute perioperative optimization trials focusing on limb-salvage versus primary amputation strategies in patients with diabetic or other metabolic-related peripheral arterial disease: these studies enroll hospitalized patients facing potential lower-limb amputation to compare immediate surgical decision pathways (revascularization attempts, limited/partial amputation, or primary transtibial/femoral amputation) and measure short-term outcomes such as reoperation, wound complications, ICU/hospital length of stay, and 30-day mortality. The patient population is typically older adults with diabetes, chronic kidney disease, or peripheral neuropathy with ischemic or infective limb-threatening pathology; results inform surgeons and hospitalists on which acute interventions reduce perioperative morbidity and resource utilization. This research is relevant to providers and payers because it targets high-cost inpatient decisions that directly affect LOS, readmission risk, and intensive resource use in DRG 618 admissions.
Comparative effectiveness studies of perioperative infection control and wound-healing strategies in metabolic-disease-related amputations: randomized or pragmatic trials evaluate different perioperative protocols (antibiotic stewardship strategies, negative-pressure wound therapy, optimized glycemic control bundles, and standardized debridement timing) in patients with diabetes-related foot infections who undergo major lower-limb amputation. These trials study inpatient and early post-discharge outcomes such as surgical site infection rates, stump healing time, need for revision/amputation level escalation, and short-term functional status, targeting a population with impaired healing physiology. Findings are directly applicable to clinical pathways and payer policies because improved protocols can reduce complications, shorten stays, and lower downstream costs associated with reoperations and extended rehabilitation.
Post-discharge rehabilitation, secondary prevention, and cost-outcome cohort studies assessing functional recovery and readmission in patients after lower-limb amputation for endocrine/metabolic disorders: prospective observational studies or randomized rehabilitation trials follow patients after discharge to compare prosthetic fitting timelines, multidisciplinary rehabilitation models, home health intensity, and secondary prevention (glycemic, vascular risk) interventions on 90- to 365-day outcomes including mobility, quality of life, prosthesis use, readmissions, and total episode-of-care costs. The enrolled population includes survivors of inpatient amputation with diabetes or metabolic comorbidities who are at high risk for recurrent limb events and hospital utilization; this research helps identify which post-acute care strategies yield the best functional and economic outcomes. Results matter to providers and payers by guiding resource allocation for durable medical equipment, rehab services, and transitional care programs that can reduce long-term costs and improve patient independence.

OpenPayer

Summary & Overview

Amputation of Lower Limb for Endocrine, Nutritional and Metabolic Disorders without CC/MCC: Inpatient Reimbursement Overview

DRG 618 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes